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the increasing availability of effective antiretroviral therapy, HIV-related mortality of people
living with HIV has markedly reduced. Liver disease has become an important cause of mortal-
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hepatitis in this defined population in Asia.
Copyright ª 2015, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.have no conflicts of interest relevant to this article.
of Microbiology, University of Hong Kong, University Pathology Building, Queen Mary Hospital, 102
.C.Y. Woo).
5.08.008
Taiwan LLC & Formosan Medical Association. All rights reserved.
Viral hepatitis in HIV-positive MSM 1155Introduction
Globally, approximately 1.4 million people die from viral
hepatitis annually.1 Although these infections may be
transmitted through various routes, many types of viral
hepatitis are transmissible by sexual contact. This is espe-
cially true in defined at-risk populations such as men who
have sex with men (MSM). Outbreaks of sexually trans-
mitted hepatitis A among MSM has been extensively re-
ported in Western countries,2e4 whereas hepatitis C has
emerged as a commonly encountered sexually transmitted
infection among MSM in the past decade, especially among
individuals with human immunodeficiency virus (HIV)-posi-
tive MSM.5,6
The highest burden of the HIV epidemic in Asia, apart
from the injecting drug-using population in Central Asia,
lies on the MSM population and is spread through sexual
transmission.7,8 With the increasing availability of effective
combination antiretroviral therapy, the mortality and
morbidity of people living with HIV has markedly
decreased.9 However, chronic liver disease has become an
important cause of mortality in the HIV-infected popula-
tion, a significant proportion of which is related to hepatitis
B and C.10,11
In this article, we review the epidemiology of sexually
transmitted viral hepatitis, including hepatitis A, B, C, and
D in the Asian HIV-positive MSM population. In addition, we
explore the emerging role of other agents, such as hepatitis
E virus (HEV), in contributing to sexually transmitted liver
diseases in endemic settings. Studies in English were iden-
tified by PubMed using the keywords “HIV,” “hepatitis,”
and “MSM,” and supplemented with references of relevant
publications.
Epidemiology of hepatitis A in HIV-positive
MSM in Asia
The endemicity of hepatitis A in Asia is widely variable,
ranging from areas of low (e.g., Japan, Singapore) and in-
termediate endemicity (e.g., Hong Kong) to high ende-
micity (e.g., India).12e14 Hepatitis A virus (HAV)
seroprevalence among general adult populations in Asia
ranges from 25.9% to 92.6%.12,15e19 Owing to the rise in
sanitation standards, the endemicity of hepatitis A in many
developing Asian countries has been decreasing over the
past 2 decades. Paradoxically, in such transitional areas
without mass vaccination programs, increasing populations
are at risk of hepatitis A, who have not contracted it as an
asymptomatic infection during childhood; this is reflected
by the outbreaks of HAV reported in Japan, Thailand,
Korea, and Singapore.16,20e22
The HAV seroprevalence among HIV-positive MSM in
Asian countries is summarized in Table 1. The reported HAV
seroprevalence ranged from 15.1% to 50.5%23e28 and, like in
the general population, was found to be associated with
increasing age.23,27 The overall prevalence was higher than
that reported in the United States (16.1%)29 but rather
comparable to that in Greece (35%).30 Although the re-
ported seroprevalence rates among HIV-positive MSM seem
to be lower than in the general Asian adult population, it
should be noted that most seroprevalence figures amongHIV-positive MSM are reported from resource-rich settings
in Asia, and from relatively young individuals who were
mostly aged < 50 years old.
Whereas outbreaks of HAV among HIV-positive MSM are
reported in Europe,31,32 they are rarely reported in Asian
countries. An outbreak involving 13 HIV-positive MSM was
reported in Japan in 1999.33 The majority (92%) of the
infected individuals was coinfected with syphilis, and some
(38.5%) had amebiasis. Although all patients recovered
from acute hepatitis A, antiretroviral therapy was inter-
rupted because of infection in a proportion (37.5%) of
patients.
Overall, with the changing endemicity of hepatitis A in
the region, a significant proportion of HIV-positive MSM,
especially young MSM who are sexually active and from
developed countries in Asia, are susceptible to the infec-
tion.34 Although reports of HAV outbreaks among Asian HIV-
positive MSM have been scarce so far, we need to remain
vigilant, given their susceptibility as well as the potential
connectivity from the sexual affiliation networking in this
at-risk population.35 Despite the reduced immunogenicity
of hepatitis A vaccine compared with HIV-uninfected
adults, immunization remains one important way to pre-
vent hepatitis A among HIV-positive MSM. Although the
extra benefit for the use of an additional dose of hepatitis A
vaccine in HIV-infected adults remains uncertain, studies
have demonstrated durable seropositive responses among
HIV-infected adults with suppressed HIV viral load and high
CD4 counts.36e38Epidemiology of hepatitis B in HIV-positive MSM
in Asia
Asia has the highest burden of hepatitis B infection in the
world.39 With the commitment of the World Health Orga-
nization Western Pacific Region Office and member coun-
tries for hepatitis B control through a childhood
immunization program, the hepatitis B surface antigen
(HBsAg) seroprevalence in children at least 5 years of age in
some Asian countries has reached the target of <2%.40
However, the disease burden of chronic hepatitis B among
the adult population remains intermediate to high in the
region, with HBsAg seroprevalence up to >8% in the adult
population.39
The HBsAg seroprevalence of HIV-positive MSM in Asia is
summarized in Table 1.23e27,41e46 It is not surprising that
the HBsAg seroprevalence among HIV-positive MSM is at
least comparable, if not higher, than in the general adult
population, given the similar route of transmission for both
infections. In regions with territory-wide universal neonatal
hepatitis B virus (HBV) immunization programs (e.g.,
Taiwan and Hong Kong), there is limited data showing that
the burden of chronic hepatitis B among HIV-positive MSM
might be on a decreasing trend over the past decade. In
Taiwan, HBsAg seroprevalence among HIV-positive MSM
born prior to and after the implementation of the universal
neonatal HBV immunization program in 1986 was 7.8% and
3.7%, respectively.41 In Hong Kong, where the universal
neonatal HBV immunization program was implemented in
1988, HBsAg seroprevalence among HIV-positive MSM in the
Table 1 Studies on seroprevalence/incidence of hepatitis A, B, C, and D in HIV-positive MSM in Asia.
References Location Period
of study
Number
tested
Seroprevalence
(%)
Incidence of infection Remarks
Hepatitis A
Lam et al [23] Hong Kong 2007e2013 1207 Anti-HAV: 37.1 d
Tseng et al [24] Taiwan 2009e2010 438 Anti-HAV: 15.1 d Seroprevalence
associated with
increasing age
Lee et al [25] Southern
Taiwan
2000e2005 75 Anti-HAV: 40 d
Sun et al [26] Taiwan 2004e2007 658 Anti-HAV: 50.5 d
Linkins et al [27] Bangkok 2006e2008 290 Anti-HAV: 32.4 d
Baek et al [28] Korea 2008e2010 77 Anti-HAV: 37.3 d Seroprevalence
associated with
increasing age
Hepatitis B
Lam et al [23] Hong Kong 2000e2013 1273 HBsAg: 9.6
Anti-HBs: 54.3
d
Sun et al [41] Taiwan 2006e2012 776a HBsAg: 7.8
Anti-HBc: 30.3
HBsAg: 3.7
Anti-HBc: 26.3
HBsAg
seroconversion:
0.486/100 py (n Z 479)
HBsAg seropositivity
associated with
syphilis and
anti-HCVþ
Tseng et al [24] Taiwan 2009e2010 438 HBsAg: 16.4 d
Lee et al [42] Southern
Taiwan
1997e2010 16 HBsAg: 6.3 d
Lee et al [25] Southern
Taiwan
2000e2005 113 HBsAg:17.7 d
Sun et al [26] Taiwan 2004e2007 658 HBsAg: 20.5 d
Fukisaki et al [46] Japan 2003e2007 394 HBsAg: 7.9 d
Chow et al [43] China 2000e2013 151 HBsAg: 18.3 d
Heng et al [44] Singapore 1990e1992 47
(46.8% MSM)
HBsAg: 8.5
Anti-HBc: 46.8
d
Linkins et al [27] Bangkok 2006e2008 290 HBsAg: 15.8
Without any
positive HBV
marker
positive: 22.4
d
Zaw et al [45] Myanmar 2005e2012 176 HBsAg: 13.4 d
Hepatitis C
Lam et al [23] Hong Kong 2000e2013 1272 Anti-HCV: 1.3 d
Lin et al [67] Hong Kong 1998e2013 1311 d Overall 2.2/1000 py
1998e2002: 1.3/1000 py
2002e2007: 1.9/1000 py
2007e2013: 4.7/1000 py
Associated with
higher education
and history of STIs
Sun et al [41] Taiwan 2006e2012 752 Anti-HCV: 3.7 d
Tseng et al [24] Taiwan 2009e2010 438 Anti-HCV: 5.5 d
Lee et al [25] Southern
Taiwan
2000e2005 113 Anti-HCV: 5.3 d
Sun et al [26] Taiwan 2004e2007 658 Anti-HCV: 6.4 d
Lee et al [42] Southern
Taiwan
1997e2010 16 Anti-HCV: 6.1 d
Sun et al [41] Taiwan 1994e2010 892
(81.9% MSM,
none IDU)
d Overall 7/1000 py
1994e2000: 0/1000 py
2001e2005: 2.3/1000 py
2006e2010: 10.1/1000 py
Associated with
syphilis
Nishijima
et al [68]
Japan 2005e2012 753 (19% IDU) d Overall 9.35/1000 py
2005e2006: 0/1000 py
2007e2008: 3/1000 py
2009e2010: 7.7/1000 py
2011e2012: 24.9/1000 py
Sensitivity analysis
(excluded IDU)
similar findings
1156 A.W.C. Lin et al.
Table 1 (continued )
References Location Period
of study
Number
tested
Seroprevalence
(%)
Incidence of infection Remarks
Chow et al [43] China 2000e2013 363 Anti-HCV: 8.4 d
Zhang et al [76] Beijing,
China
2005e2006 16 Anti-HCV: 18.8 d % of IDU not well
described
An et al [77] China NA 513 Anti-HCV: 1.94 d
Zhao et al [78] Shandong,
China
2000e2010 230 Anti-HCV: 24.3 d Associated with
syphilis; % of IDU
not well described
Lim et al [79] Singapore 2006e2011 739
(33.7% MSM)
Anti-HCV: 2 d
Zaw et al [45] Myanmar 2005e2012 176 Anti-HCV: 3.4 d
Hepatitis D
Hung et al [85] Taiwan 1992e2012 257 Anti-HDV: 7.4 Overall 9.07/1000 pyb
1992e2001: 0/1000 py
2002e2006: 3.91/1000 py
2007e2012: 13.6/1000 py
Associated with
elevated RPR
Lee et al [86] Southern
Taiwan
2009e2012 51 Anti-HDV: 7.8 d
Hepatitis E
Liu et al [87] Taiwan 2011 1371 Anti-HEV: 6.3
HAVZ hepatitis A virus; HBSAgZ hepatitis B surface antigen; HBVZ hepatitis B virus; HCVZ hepatitis C virus; HDVZ hepatitis D virus;
HEV Z hepatitis E virus; HIV Z human immunodeficiency virus; IDU Z injecting drug users; MSM Z men who have sex with men;
py Z person-years; NA Z not applicable; RPR Z rapid plasma reagin; STI Z sexually transmitted infection.
a Among the 776 patients, 244 were born before 1986, 532 were born after 1986.
b Among a total of 375 patients.
Viral hepatitis in HIV-positive MSM 1157largest HIV clinic was 12.3%, 10.1%, and 8.3% in the period
2000e2004, 2005e2009, and 2010e2013, respectively.
Compared with those who acquired HIV via the hetero-
sexual route, HIV-positive MSM seemed to have higher
prevalence of hepatitis B. Most studies, which also include
the data of those who acquired HIV via the heterosexual
route, showed a higher proportion of HIV-positive MSM with
positive HBV markers compared with HIV-positive hetero-
sexuals. A study from Singapore showed that 72.7% HIV-
positive MSM versus 48% HIV-positive heterosexuals tested
positive for HBV markers (HBsAg and/or anti-HBs and/or
Hepatitis B core antibody (anti-HBc)).44 A Taiwanese study
found that HBsAg prevalence among HIV-positive MSM and
heterosexuals was 17.7% and 12.8%, respectively,24
whereas another study from Myanmar showed HBsAg sero-
prevalence of 13.4% and 9%, respectively.45 However, a
report from Hong Kong showed a higher HBsAg seropreva-
lence among HIV-positive heterosexual males (12.1%) than
MSM (9.6%), probably owing to the younger age in the latter
group.23
Data regarding the HBV genotype among HIV-positive
MSM in Asia are limited. Similar to the majority of the Asian
hepatitis B carrying general population,47 HBV genotypes B
and C are the most commonly found genotypes in the HIV-
infected population in Taiwan.48 However, studies from
Japan showed that genotype A, the predominant genotype
among MSM in Europe, might be more commonly found
among HIV-positive MSM. In 2001, genotype A was reported
as predominantly found in HIV-positive MSM, in contrast to
other genotypes found among HIV-positive heterosexual or
hemophiliac patients.49 More recent data also showed thatgenotype A was the major circulating HBV genotype among
HIV-positive MSM in Japan.46 The predominant HBV geno-
type among HIV-positive MSM in other Asian countries is
unknown.
Not surprisingly, the burden of HIVeHBV coinfection
among MSM in Asia is significant. Despite limited data on
decreasing trend of HBsAg seropositivity in HIV-positive
MSM in regions with the universal neonatal HBV immuniza-
tion program, the impact on the overall epidemiology of
HIVeHBV coinfection among MSM in Asia is still uncertain.
Moreover, serological markers for HBV are associated with
host immunity and viral activities.50 Thus, screening for
HBV infection and recommendations on vaccination, espe-
cially with the use of increased dose to enhance serological
response,51,52 for HBV susceptible HIV-positive MSM remains
important. Furthermore, the use of antiretroviral therapy
might also influence the epidemiology of hepatitis B in HIV-
positive MSM. In a study reported from Taiwan, none of the
133 HIV-positive MSM on antiretroviral therapy with lam-
ivudine and/or tenofovir developed HBsAg seroconversion
during a follow-up period up to 6 years.41 Another two
studies from Taiwan also found a lower incidence of HBV
infection among those who were on lamivudine- or
tenofovir-containing regimen.53,54Epidemiology of hepatitis C in HIV-positive
MSM in Asia
Hepatitis C virus (HCV) has emerged as a sexually trans-
mitted infection among HIV-positive MSM in the West. Since
1158 A.W.C. Lin et al.2000, outbreaks of HCV among HIV-positive MSM who denied
injecting drug use have been reported from the United
States,55,56 Europe,57,58 and Australia.59 The HCV incidence
in HIV-positive MSM increased from 1 to 3/1000 patient-
years (py) in the late 1990s to >10/1000 py from the
early 2000s onward.60 Certain risk factors associated with
infection identified included unsafe sex, fisting, and sexu-
ally transmitted infections.61e65
A similar trend has also been reported in Asia recently. In
2012, a Taiwanese study described an increasing incidence of
hepatitis C in HIV-infected patients, and among them >80%
were MSM.66 Similar findings were reported from Hong Kong
and Japan.67,68 All of them showed a rise in the incidence of
hepatitis C among HIV-positive MSM in the past decade.
Moreover, syphilis was found to be an independent factor
associated with incident hepatitis C in Taiwan and Hong
Kong, and higher education level was another independent
factor found in the study from Hong Kong.67 These reporting
of HCV as a sexually transmitted infection among HIV-
positive MSM in these resource-rich settings in Asia echoed
the changing epidemiology of hepatitis C in Western coun-
tries where improved survival and serosorting were proposed
to be contributing factors for the increasing prevalence of
sexually transmitted infections including HCV.69 The survival
of people living with HIV has improved with the accessibility
of antiretroviral therapy and good medical care in Asia,
especially in resource-rich settings.9,70 However, the prac-
tice of serosorting among HIV-positive MSM, which is well
recognized in Western countries, is largely unknown in Asia.
Only one study fromTaiwan reported that 27% of HIV-positive
MSM under medical care practiced serosorting.71
HCV genotypes 1a and 4d are the predominant geno-
types in sexually transmitted HCV in HIV-positive MSM in
Europe, and there is robust evidence on MSM-specific
clustering.60,72,73 Genotype 1a predominates in HIV-
positive MSM in the United States, but there is a lack of
information on clustering.74 Genotype 3a is more prevalent
among Australian HIV-positive MSM, however, around one
half of the acute HCV infections among HIV-positive MSM in
Australia were attributed to injecting drug use instead of
sexual transmission.59 In Asia, limited data found evidence
of transmission clusters among HIV-positive MSM, but with
different genotypes compared with those found in Western
countries. In the Taiwanese study, the phylogenetic anal-
ysis revealed seven HCV transmission clusters or pairs (4
within genotype 1b, 2 within genotype 2a, and 1 within
genotype 3a),66 and a monophyletic cluster of HCV-3a
lineage was found among HIV-positive MSM in Hong Kong.75
Although incident HCV has been increasingly reported,
the anti-HCV seroprevalence rates among HIV-positive MSM
in most Asian countries were <10% (Table
1).23e27,41e45,67,68,76e79 Two studies from China reported
an exceptionally high anti-HCV seroprevalence of 18.8% and
24.3%, however, the injecting drug use in these studies was
not well described.76,78Epidemiology of hepatitis D in HIV-positive
MSM in Asia
Hepatitis D virus (HDV) requires the presence of HBV to
cause infection in humans, and is mainly transmittedthrough parenteral and sexual routes.80 In the early 1990s,
heterosexual exposure was found to be an effective route
of transmission of HDV in the general population.81,82
Among the HIV-infected population, HDV infection
occurred mainly among injecting drug users.83,84 Studies on
the seroprevalence of anti-HDV among HIV-positive MSM are
limited. Two recent studies from Taiwan reported the anti-
HDV seroprevalence to be 7.4% and 7.8% among HIV-positive
MSM,85,86 which was higher than the 3.2% rate reported in
Europe.70 In these two studies, the anti-HDV seropreva-
lence among HIV-positive injecting drug users was 44% and
25%, respectively. One of these studies revealed a signifi-
cant increase in the incidence of HDV infection in the study
cohort from 2007 onward. Moreover, recent HDV infection
was found to be associated with elevated rapid plasma
reagin titers.85Epidemiology of hepatitis E in HIV-positive MSM
in Asia
Little is known about the epidemiology of hepatitis E among
Asian HIV-positive MSM. Data from Taiwan indicate a sero-
prevalence of 6.3% and 4.0% among HIV-infected and HIV-
uninfected MSM, respectively.87 In the Asian setting, hep-
atitis E epidemiology has two faces. It remains a water-
borne disease with person-to-person transmission in most
parts of South and Southeast Asia; in these regions, MSM are
at risk of direct acquisition of hepatitis E through practices
such as oroanal sex. However, in industrialized Asian
countries such as Japan, hepatitis E usually manifests as
sporadic autochthonous infection caused by the consump-
tion of meat derived from an increasing range of animal
reservoirs of HEV.88,89 Whereas fecaleoral human-to-
human transmission of such autochthonous hepatitis E is
generally considered to be limited, it is notable that MSM
were found to be at an increased risk of acquiring hepatitis
E irrespective of their HIV status in the United Kingdom, a
region where hepatitis E is autochthonous and foodborne.90
Further studies are required to assess the epidemiology
of hepatitis E in the Asian MSM population. This is particu-
larly important, as there is evidence to suggest that HEV
superinfection in Asian hepatitis B carriers tends to produce
clinically severe liver disease,91 a feature of relevance to
the MSM population at risk of hepatitis B acquisition.
Furthermore, HIV-positive patients with low CD4 counts
stand a low, but well-defined, risk of chronic hepatitis E
carriage with progression to liver cirrhosis.92 Therefore,
hepatitis E is likely to be a condition of emerging impor-
tance in the HIV-positive MSM population. Studies on the
efficacy of the recently developed hepatitis E vaccine93,94
suggest that it may be useful in prevention of hepatitis E
among healthy MSM; however, the efficacy of the vaccine
among HIV-infected MSM remains to be elucidated.Conclusion
Asian countries are diverse in terms of socioeconomic
conditions and availability of healthcare. In resource-rich
settings, the epidemiology of sexually transmitted viral
hepatitis in HIV-positive MSM parallels the evolution of the
Viral hepatitis in HIV-positive MSM 1159situation in developed countries in other parts of the world.
However, there are also unique features in the disease
burden and molecular epidemiology of sexually transmitted
viral hepatitis in Asia. Overall, viral hepatitis is increasingly
recognized as a sexually transmitted infection among Asian
HIV-positive MSM. Enhanced surveillance and targeted
prevention of viral hepatitis including improved sanitation
and food safety, safer sex, and vaccination is becoming
increasingly essential in HIV care in this part of the world.Acknowledgments
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